DLGAP5 and neoplasm: Immunohistochemical (IHC) staining revealed increased DLGAP5 expression in post-treatment tumor samples compared to pre-treatment samples, suggesting a critical role for DLGAP5 in GEM resistance of BLCA (Figure 1A).